{"0EH.F": {"short_name": "TOLERANZIA AB", "long_name": "Toleranzia AB", "summary": "Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. The company is headquartered in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "5J2.F": {"short_name": "GABATHER AB (PUBL) SK-,44", "long_name": "Gabather AB (publ)", "summary": "Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was founded in 2014 and is based in Malm\u00c3\u00b6, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "6FN.F": {"short_name": "KLARIA PHARMA HOLDING AB", "long_name": "Klaria Pharma Holding AB (publ.)", "summary": "Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Uppsala"}, "AC6.F": {"short_name": "ALZECURE PHARMA AB", "long_name": "AlzeCure Pharma AB (publ)", "summary": "AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of diseases and conditions that affect the central nervous system. The company is developing five drug candidates based on the NeuroRestore and Alzstatin research platforms. Its pipeline drug candidates include ACD855, which is in Phase I clinical trial for sleep disruptions, traumatic brain injuries, and Alzheimer's disease; ACD856, ACD679, and ACD680 for Alzheimer's disease; ACD857 for eye/ear indications; VR1 that is in Phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Huddinge"}, "ALZCUR.ST": {"short_name": "AlzeCure Pharma AB", "long_name": "AlzeCure Pharma AB (publ)", "summary": "AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of diseases and conditions that affect the central nervous system. The company is developing five drug candidates based on the NeuroRestore and Alzstatin research platforms. Its pipeline drug candidates include ACD855, which is in Phase I clinical trial for sleep disruptions, traumatic brain injuries, and Alzheimer's disease; ACD856, ACD679, and ACD680 for Alzheimer's disease; ACD857 for eye/ear indications; VR1 that is in Phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Huddinge"}, "B6E.F": {"short_name": "SWEDISH ORPHAN BIOVIT.SK1", "long_name": "Swedish Orphan Biovitrum AB (publ)", "summary": "Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases. The company offers Alprolix for haemophilia B; Doptelet for chemotherapy induced thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. It also develops drug substance for ReFacto AF; BIVV001 for haemophilia A; BIVV0023 for haemophilia B; and Nirsevimab for respiratory syncytial virus. The company operates in Europe, North America, the Middle East, Russia, North Africa, and Asia. It has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Solna"}, "BGAIF": {"short_name": "BIOGAIA AG", "long_name": "BioGaia AB (publ)", "summary": "BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of baby and child care, including infantile colic, infections, functional abdominal pain, diarrhea, functional constipation, and regurgitation; gut health comprising diarrhoea and constipation; gastrointestinal health consisting of Helicobacter pylori\u00c2\u0096the gastric ulcer bacterium; and oral health, including gingivitis and periodontitis, caries, and halitosis. The company offers its products under the brand name of BioGaia through pharmacies and retail outlets. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Stockholm"}, "BIOG-B.ST": {"short_name": "BioGaia AB ser. B", "long_name": "BioGaia AB (publ)", "summary": "BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of baby and child care, including infantile colic, infections, functional abdominal pain, diarrhea, functional constipation, and regurgitation; gut health comprising diarrhoea and constipation; gastrointestinal health consisting of Helicobacter pylori\u00c2\u0096the gastric ulcer bacterium; and oral health, including gingivitis and periodontitis, caries, and halitosis. The company offers its products under the brand name of BioGaia through pharmacies and retail outlets. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "BIOGY": {"short_name": "BIOGAIA AG", "long_name": "BioGaia AB (publ)", "summary": "BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of baby and child care, including infantile colic, infections, functional abdominal pain, diarrhea, functional constipation, and regurgitation; gut health comprising diarrhoea and constipation; gastrointestinal health consisting of Helicobacter pylori\u00c2\u0096the gastric ulcer bacterium; and oral health, including gingivitis and periodontitis, caries, and halitosis. The company offers its products under the brand name of BioGaia through pharmacies and retail outlets. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Stockholm"}, "BIOVF": {"short_name": "SWEDISH ORPHAN BIOVITRUM AB", "long_name": "Swedish Orphan Biovitrum AB (publ)", "summary": "Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases. The company offers Alprolix for haemophilia B; Doptelet for chemotherapy induced thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. It also develops drug substance for ReFacto AF; BIVV001 for haemophilia A; BIVV0023 for haemophilia B; and Nirsevimab for respiratory syncytial virus. The company operates in Europe, North America, the Middle East, Russia, North Africa, and Asia. It has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Solna"}, "C5G.F": {"short_name": "OREXO AB  SK-,40", "long_name": "Orexo AB (publ)", "summary": "Orexo AB (publ), a specialty pharmaceutical company, and its subsidiaries develop and commercialize pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX338 sublingual tablet formulation of ketorolac for acute treatment of moderate to severe pain; and OX382, an oral formulation of buprenorphine and naloxone for treatment of opioid dependence. It is also developing OX-MPI program that has lead candidate drug BI1029539, an anti-inflammatory compound targeting microsomal prostaglandin E synthase. The company's digital therapies comprise OXD01 for opioid use disorder and OXD02/vorvida for alcohol use disorder. Orexo AB (publ) has partnerships with Lyfebulb to recover from alcohol and opioid use disorders; and GoGoMeds to provide digital therapies deprexis and vorvida available for the treatment of depression and management of problematic alcohol misuse. The company was founded in 1995 and is headquartered in Uppsala, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Uppsala"}, "CALT": {"short_name": "Calliditas Therapeutics AB", "long_name": "Calliditas Therapeutics AB (publ)", "summary": "Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "NMS", "market": "us_market", "country": "Sweden", "city": "Stockholm"}, "CALTX.ST": {"short_name": "Calliditas Therapeutics AB", "long_name": "Calliditas Therapeutics AB (publ)", "summary": "Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "EN9.F": {"short_name": "ENZYMATICA AB", "long_name": "Enzymatica AB", "summary": "Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Its product includes ColdZyme mouth spray, which prevents cold and reduces the duration of common cold. The company also provides ColdZyme mouth spray under the PreCold name in Iceland; Cortagrip name in Spain; ViruProtect name in Austria and Belgium; and ColdGuard name in South Africa. The company also offers STADAProtect, a mouth spray to protect and care oral cavity, as well as enzyme formulations. Enzymatica AB was founded in 2007 and is based in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "ENZY.ST": {"short_name": "Enzymatica AB", "long_name": "Enzymatica AB", "summary": "Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Its product includes ColdZyme mouth spray, which prevents cold and reduces the duration of common cold. The company also provides ColdZyme mouth spray under the PreCold name in Iceland; Cortagrip name in Spain; ViruProtect name in Austria and Belgium; and ColdGuard name in South Africa. The company also offers STADAProtect, a mouth spray to protect and care oral cavity, as well as enzyme formulations. Enzymatica AB was founded in 2007 and is based in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "ERMA.ST": {"short_name": "Enorama Pharma AB", "long_name": "Enorama Pharma AB (publ)", "summary": "Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in Malm\u00c3\u00b6, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "GABA.ST": {"short_name": "Gabather AB", "long_name": "Gabather AB (publ)", "summary": "Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was founded in 2014 and is based in Malm\u00c3\u00b6, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "KARO.ST": {"short_name": "Karo Pharma AB", "long_name": "Karo Pharma AB (publ)", "summary": "Karo Pharma AB (publ) develops and markets prescription drugs, over-the-counter products, medical devices, and hospital supply products for pharmacies and the health care sectors in Sweden, Norway, Denmark, Finland, France, rest of Europe, the United States, and internationally. Its prescription drugs include Mollipect and TheoDur for respiratory diseases; Probecid for gout; Burinex, Centyl K, Kaleorid, Suscard, Nitroglycerin BioPhausia, and Digoxin BioPhausia for cardiovascular diseases; Laxabon and Egazil for gastro/intestinal diseases; Condyline, Synalar, Mildison, Fonx, and Conotrane for dermatology diseases; Paraflex for musculoskeletal diseases; Dolerin, Citodon, Morfin Special, Paralgin forte, and Trampalgin for pain; Ibux, Paracet, and Viruseptin for pain, cough, and cold; Bronkyl and Bronkyl forte for cold/flu diseases; Selexid for antibiotics; Solvezink for zinc deficiency; Lithionit for CNS/psychiatry diseases; Metformin for diabetes; and Zonat for insomnia. The company also offers BabySlide, a medical device; Dosett, a solution for the storage of medicine; Mabs compression socks; and Swereco, which offers a product assortment of ergonomic products for people with disabilities. In addition, it provides skin care products, such as CCS gel, Decubal, Fungobase, Fungoral, Karbasal, KidsClin, Locobase, Oliva, PoxClin, and Propyless; foot care products, including CCS, Cortimyk, Footner, Nailner, and Wortie; and intimate care products comprising HemoClin, Multi-Gyn, Asan, Multi-Mam, and Pevaryl. Further, the company offers nutritional and wellness products, such as All\u00c3\u00a9vo, Bamse, Betavivo, Clinomyn, DAX, Dosett, Flux, Dailycare/Lactocare, and Indy Beauty. It sells its products to retailers, pharmacies, and hospitals, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was founded in 1987 and is based in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "KLAR.ST": {"short_name": "Klaria Pharma Holding AB", "long_name": "Klaria Pharma Holding AB (publ.)", "summary": "Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "LC8A.F": {"short_name": "CALLIDITAS THERAP. AD 1/2", "long_name": "Calliditas Therapeutics AB (publ)", "summary": "Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "MB8A.F": {"short_name": "MOBERG PHARMA AB", "long_name": "Moberg Pharma AB (publ)", "summary": "Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products for skin diseases in Sweden, the United States, and internationally. It develops MOB-015, which is under Phase III clinical trial for the treatment of nail fungus treatment; and BUPI, a lozenge with bupivacaine intended for pain relief in association with inflammation and ulceration of the oral mucous membranes. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was founded in 2006 and is headquartered in Bromma, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Bromma"}, "MOB.ST": {"short_name": "Moberg Pharma AB", "long_name": "Moberg Pharma AB (publ)", "summary": "Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products for skin diseases in Sweden, the United States, and internationally. It develops MOB-015, which is under Phase III clinical trial for the treatment of nail fungus treatment; and BUPI, a lozenge with bupivacaine intended for pain relief in association with inflammation and ulceration of the oral mucous membranes. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was founded in 2006 and is headquartered in Bromma, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Bromma"}, "NANEXA.ST": {"short_name": "Nanexa AB", "long_name": "Nanexa AB", "summary": "Nanexa AB engages in the development of drug delivery systems worldwide. It operates PharmaShell, a nanobased drug delivery platform that is based on a coating technique called atomic layer deposition. The company offers a gas barrier that prevents xenon gas from penetrating detectors used in this assay equipment; and a coating system for medical polymeric products that protects against fungal spreads, such as the common fungal genus Candida. Nanexa AB was founded in 2007 and is based in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "OASM.ST": {"short_name": "Oasmia Pharmaceutical AB", "long_name": "Oasmia Pharmaceutical AB (publ)", "summary": "Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company offers Apealea/Paclical for the treatment of ovarian cancer that has completed phase III clinical trial, as well as in phase I clinical trial for the treatment of metastatic breast cancer; and Docetaxel micellar, a patented formulation of cytostatic docetaxel in combination with XR-17 that has completed pre-clinical trial for the treatment of prostate cancer. It also provides Doxophos, a patented formulation of cytostatic doxorubicin in combination with XR-17 Doxorubicin for the treatment of various forms of cancers, including blood, skeleton, breast, prostate, and lungs; and KB9520, a substance that is in pre-clinical stage to reduce the side effects of cytostatics treatment. In addition, the company's animal health product portfolio includes Paccal Vet, a patented formulation of paclitaxel for the treatment of mammary carcinoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma. Additionally, its technology platform portfolio comprises XR-19, an internal technology, which is under assessment process for a dual encapsulation technology; and XR-17, a proprietary solubility-enhancing technology platform in oncology and other therapeutic areas. Oasmia Pharmaceutical AB (publ) was founded in 1988 and is headquartered in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "OASMY": {"short_name": "OASMIA PHARMACEUTICAL AB SPON A", "long_name": "Oasmia Pharmaceutical AB (publ)", "summary": "Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company offers Apealea/Paclical for the treatment of ovarian cancer that has completed phase III clinical trial, as well as in phase I clinical trial for the treatment of metastatic breast cancer; and Docetaxel micellar, a patented formulation of cytostatic docetaxel in combination with XR-17 that has completed pre-clinical trial for the treatment of prostate cancer. It also provides Doxophos, a patented formulation of cytostatic doxorubicin in combination with XR-17 Doxorubicin for the treatment of various forms of cancers, including blood, skeleton, breast, prostate, and lungs; and KB9520, a substance that is in pre-clinical stage to reduce the side effects of cytostatics treatment. In addition, the company's animal health product portfolio includes Paccal Vet, a patented formulation of paclitaxel for the treatment of mammary carcinoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma. Additionally, its technology platform portfolio comprises XR-19, an internal technology, which is under assessment process for a dual encapsulation technology; and XR-17, a proprietary solubility-enhancing technology platform in oncology and other therapeutic areas. Oasmia Pharmaceutical AB (publ) was founded in 1988 and is headquartered in Uppsala, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Uppsala"}, "ORX.ST": {"short_name": "Orexo AB", "long_name": "Orexo AB (publ)", "summary": "Orexo AB (publ), a specialty pharmaceutical company, and its subsidiaries develop and commercialize pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX338 sublingual tablet formulation of ketorolac for acute treatment of moderate to severe pain; and OX382, an oral formulation of buprenorphine and naloxone for treatment of opioid dependence. It is also developing OX-MPI program that has lead candidate drug BI1029539, an anti-inflammatory compound targeting microsomal prostaglandin E synthase. The company's digital therapies comprise OXD01 for opioid use disorder and OXD02/vorvida for alcohol use disorder. Orexo AB (publ) has partnerships with Lyfebulb to recover from alcohol and opioid use disorders; and GoGoMeds to provide digital therapies deprexis and vorvida available for the treatment of depression and management of problematic alcohol misuse. The company was founded in 1995 and is headquartered in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "ORXOY": {"short_name": "OREXO AB", "long_name": "Orexo AB (publ)", "summary": "Orexo AB (publ), a specialty pharmaceutical company, and its subsidiaries develop and commercialize pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX338 sublingual tablet formulation of ketorolac for acute treatment of moderate to severe pain; and OX382, an oral formulation of buprenorphine and naloxone for treatment of opioid dependence. It is also developing OX-MPI program that has lead candidate drug BI1029539, an anti-inflammatory compound targeting microsomal prostaglandin E synthase. The company's digital therapies comprise OXD01 for opioid use disorder and OXD02/vorvida for alcohol use disorder. Orexo AB (publ) has partnerships with Lyfebulb to recover from alcohol and opioid use disorders; and GoGoMeds to provide digital therapies deprexis and vorvida available for the treatment of depression and management of problematic alcohol misuse. The company was founded in 1995 and is headquartered in Uppsala, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Uppsala"}, "PROB.ST": {"short_name": "Probi AB", "long_name": "Probi AB (publ)", "summary": "Probi AB (publ), a bioengineering company, researches, develops, manufactures, markets, and sells probiotics for food, health, and pharmaceutical companies. The company operates in two segments, Consumer Healthcare and Functional Food. It conducts research primarily in the fields of gut health, immune system, nutrient absorption, iron absorption, bone health, and stress and recovery. The company provides dietary supplement, and food and beverage products in the form of capsules, tablets, chewable tablets, spheres, fast melt sticks, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. It sells its products approximately in 40 countries worldwide. Probi AB (publ) has a development agreement with Cilag GmbH International for the development of probiotic products; and collaboration with \u00c3\u0096rebro University for research into exploration of novel, needle free vaccines. The company was founded in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "RLS.ST": {"short_name": "RLS Global AB", "long_name": "RLS Global AB (publ)", "summary": "RLS Global AB (publ), a medical technology company, develops and sells products for the treatment of diseases in wound and dental care in Sweden. Its products include ChloraSolv that is used for the treatment of chronic foot and leg ulcers for diabetic patients; PeriSolv for the treatment of periodontitis, peri-implant mucositi, and peri-implantitis; and CariSolv, a gel used for treating caries. The company was founded in 1996 and is based in M\u00c3\u00b6lndal, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "M\u00c3\u00b6lndal"}, "SECARE.ST": {"short_name": "Swedencare AB", "long_name": "Swedencare AB (publ)", "summary": "Swedencare AB (publ), together with its subsidiaries, develops, manufactures, distributes, and sells healthcare products. It offers ProDen PlaqueOff powder, a food supplement for cats and dogs, which reduce the formation of plaque and tartar; ProDen PlaqueOff dental bites, a pet dental product; ProDen PlaqueOff Powder Cat; ProDen PlaqueOff dental bones for dogs; and ProDen PlaqueOff Mini Dental Care Bones, a chewy bone for smaller dogs. The company also provides dietary supplements for cat, dog, and horse under the NutriScience brand, such as Stomax, which enhance digestion; ArthriAid Omega HA and Glucosamine for joints mobility; RevitalAid, a multivitamin supplement; SeniorAid for joint mobility, brain function, immune systems, and nutritional support; KalmAid, which helps to calm anxious and troubled pets; and OmegaAid used for treatment of skin and fur diseases. In addition, it develops and manufactures equine supplements. Further, the company provides ProDen PlaqueOff teeth and gums, a natural food supplement to enhance dental hygiene and prevent tartar buildup for human. It distributes its products through pharmacies, veterinary clinics, pet shops, wholesalers, and online. Swedencare AB (publ) is headquartered in Malm\u00c3\u00b6, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "SOBI.ST": {"short_name": "Swedish Orphan Biovitrum AB", "long_name": "Swedish Orphan Biovitrum AB (publ)", "summary": "Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases. The company offers Alprolix for haemophilia B; Doptelet for chemotherapy induced thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. It also develops drug substance for ReFacto AF; BIVV001 for haemophilia A; BIVV0023 for haemophilia B; and Nirsevimab for respiratory syncytial virus. The company operates in Europe, North America, the Middle East, Russia, North Africa, and Asia. It has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "TOL.ST": {"short_name": "Toleranzia AB", "long_name": "Toleranzia AB", "summary": "Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. The company is headquartered in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}}